Noteworthy is the complete remission of CNS inflammation (patient 2), arthritis (patient 3), and ILD (patient 3) as well as the improvement of trachyonychia (patient 4) under baricitinib, whose effectiveness for STAT3-GOF-associated immune dysregulation has not been reported previously. The gene discussed is STAT3; the disease is nonsyndromic congenital nail disorder 1.